The Use of Biologic Agents for the Treatment of Cutaneous Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Review of Reported Cases
Pach J, Valido K, Belzer A, Leventhal J. The Use of Biologic Agents for the Treatment of Cutaneous Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Review of Reported Cases. American Journal Of Clinical Dermatology 2024, 25: 595-607. PMID: 38767827, DOI: 10.1007/s40257-024-00866-z.Peer-Reviewed Original ResearchCutaneous immune-related adverse eventsImmune-related adverse eventsAdverse eventsAntitumor responseBiological agentsHigh-dose systemic corticosteroidsSevere cutaneous adverse reactionsImmune checkpoint inhibitorsStevens-Johnson syndromeCutaneous adverse reactionsAdverse event patternEnglish-language literatureTransient acantholytic dermatosisTreating high-gradeSpectrum of dermatologic manifestationsCheckpoint inhibitorsSystemic corticosteroidsCorticosteroid-sparingImmunobullous disordersPsoriasiform eruptionLichenoid reactionsEczematous dermatitisLichenoid eruptionDermatological manifestationsHigh-gradeThe Impact of Dermatologic Adverse Events on the Quality of Life of Oncology Patients: A Review of the Literature
Belzer A, Pach J, Valido K, Leventhal J. The Impact of Dermatologic Adverse Events on the Quality of Life of Oncology Patients: A Review of the Literature. American Journal Of Clinical Dermatology 2024, 25: 435-445. PMID: 38366030, DOI: 10.1007/s40257-024-00847-2.Peer-Reviewed Original ResearchDermatologic adverse eventsAdverse eventsQuality of lifeManagement of dermatologic adverse eventsDiscontinuation of treatmentDermatology Life Quality IndexQuality of life of oncological patientsLife Quality IndexRadiation therapyCytotoxic chemotherapyDose reductionOral mucosaTargeted therapyOncological therapyProphylactic treatmentDrug classesEarly managementOncology patientsPatientsQuality-of-life concernsLife-prolonging treatmentTherapyPatient well-beingDeclining quality of lifeImpact patients